high blood pressure1
14 Sep 2017
Re: Anyone else in here? Disappointing news...Holding though as plenty of cash and things could change quickly. The tone of delivery could not be more down beat of they tried though so I am considering an exit
high blood pressure1
11 Aug 2017
Anyone else in here? I bought at 50p and expecting good things by 2020
Sambram
13 Sep 2016
Hardman & Co update "Abzena is an integrated group offering a broad range of services and technologies to improve the chances of discovering and developing effective biopharmaceutical drugs. With strong footprints in both the US and UK, the company provides a feefor-service offering with the aim of embedding its technology – ‘Abzena Inside’ – into commercial products on which it will derive a long-term royalty stream. To date, from 40 technology agreements, partners have initiated clinical development with 12 ‘Abzena Inside’ products. The service business easily covers the current valuation suggesting that the significant royalty stream is in the price for nothing."Hardman & Co put out a note this morning on Research Tree
pharmaspecialist
07 Sep 2016
Valuation Over a year has passed and still nothing to really indicate how this company should be valued by private investors. I think the CEO, John Burt, is being refreshingly honest in the 2016 Annual Report when he says "During the next few years we expect to see the validation of our integrated business model....." in other words it is not clear whether the approach being used by the company will work from a financial viewpoint. He also says "the business is on a trajectory to profitability" which I think is something that all biotech companies would say! My opinion is that it is still too early to invest but I am pleased to see that progress in terms of deals and agreements is apparently being made and capacity is being expanded.
Simbrad
22 Jun 2016
"FY16 results were strong, with 28% like-for-like total revenue growth reported (74% growth including the £2.7m contribution from its acquisitions late 2015). It has been a pivotal year for Abzena as it has expanded its business to provide a broad range of services from antibody discovery through to GMP manufacturing for Phase I/II trials. Alongside this, its clinical Abzena inside pipeline continues to grow, with 11 products now in the clinic and progressing toward commercialisation, most notably GS-5745 in gastric cancer." Note out from Edison yesterday on research tree
pharmaspecialist
23 Jun 2015
Valuation Today's paid for analyst report from Edison is correct in saying that the Abzena's technology licenses are the key to its long term value. They also help support the company's current valuation. The problem is that the details of these licenses are not available to investors such as ourselves. Edison describes them as a small percentage of royalties sales but without knowing the percentage it is impossible to value the company. My guess is that the percentage is so low that the drug would have to be a very big seller to enable Abzena to get anywhere near profitability. Unfortunately the company has not had, and still does not have, enough money to develop products far enough to negotiate decent sales royalties with bigger companies. My impression is that Abzena is a service provider which will need alot of luck if it is ever to achieve significant sales royalties. There is an argument that it should revert to a pure service provider model as it could well show growing profitability on this basis.
